NYSE:TAK Takeda Pharmaceutical Q4 2025 Earnings Results & Report $18.86 +0.34 (+1.81%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more. Takeda Pharmaceutical reported Q4 2025 earnings on March 31, 2026. The company reported EPS of $0.5610, while revenue was $6.90 billion. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 31, 2026TimeBefore Market Opens Takeda Pharmaceutical EPS ResultsActual EPS$0.5610Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate4 of last 7 quartersTakeda Pharmaceutical Revenue ResultsActual Revenue$6.90 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTakeda Pharmaceutical's Q2 2027 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2027 Earnings ReportConference Call ResourcesEarnings HistoryCompany Profile Takeda Pharmaceutical Q4 2025 Earnings FAQ Did Takeda Pharmaceutical beat earnings estimates for Q4 2025? Takeda Pharmaceutical (NYSE:TAK) reported earnings of $0.5610 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026. What was Takeda Pharmaceutical's revenue for Q4 2025? Takeda Pharmaceutical reported revenue of $6.90 billion for Q4 2025. When is Takeda Pharmaceutical's next earnings date? Takeda Pharmaceutical's next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Takeda Pharmaceutical on the company's earnings history page. Takeda Pharmaceutical Earnings HeadlinesTakeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust PipelineOctober 13 at 4:00 PM | seekingalpha.comTakeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% RunOctober 1, 2026 | finance.yahoo.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in NepalOctober 1, 2026 | tmcnet.comWill Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline NarrativeOctober 1, 2026 | finance.yahoo.comTakeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis DataSeptember 30, 2026 | finance.yahoo.comSee More Takeda Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Takeda Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Takeda Pharmaceutical and other key companies, straight to your email. Email Address About Takeda PharmaceuticalTakeda Pharmaceutical (NYSE:TAK) Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder. The company also develops plasma-derived therapies and vaccines through its research and manufacturing operations. Founded in Osaka in 1781 by Chobei Takeda I, Takeda has evolved from a traditional Japanese medicine business into a multinational biopharmaceutical company. Its medicines and services are available in Japan, the United States, Europe and other markets worldwide. Takeda’s global expansion was significantly strengthened by its acquisition of Shire plc, completed in 2019. Christophe Weber has served as the company’s president and chief executive officer since 2014.View Takeda Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
